- 全部删除
- 您的购物车当前为空
DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability.
为众多的药物研发团队赋能,
让新药发现更简单!
DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 3,630 | 5日内发货 | |
5 mg | ¥ 4,570 | 5日内发货 | |
25 mg | ¥ 17,600 | 10-14周 | |
50 mg | ¥ 22,900 | 10-14周 | |
100 mg | ¥ 31,500 | 10-14周 | |
1 mL x 10 mM (in DMSO) | ¥ 4,930 | 5日内发货 |
产品描述 | DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability. |
靶点活性 | DLK:ki:3 nM |
分子量 | 423.43 |
分子式 | C20H24F3N5O2 |
CAS No. | 1620574-24-4 |
密度 | 1.59 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 62.5 mg/mL (147.60 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容